In a report released yesterday, Yigal Nochomovitz from Citi maintained a Hold rating on Krystal Biotech, with a price target of $198.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yigal Nochomovitz has given his Hold rating due to a combination of factors. The revenue from Vyjuvek in the third quarter of 2025 slightly exceeded expectations, driven by early sales in Germany. However, the U.S. market faced challenges with launch-maturation, resulting in flat or declining quarter-over-quarter performance. Despite these challenges, the expansion of the U.S. salesforce has shown potential in increasing patient starts beyond the centers-of-excellence, with a notable rise in reimbursement approvals.
In Europe, growth is anticipated to be gradual, with pricing negotiations expected to extend into the second half of 2026 in countries like Germany, France, and Italy. While the current stock valuation is deemed fair, there is potential for reassessment based on future pipeline developments, particularly with KB801 in NK, which is expected to show a differentiated efficacy profile by mid-2026. This potential development could lead to a more positive outlook on the stock if the data is favorable.
Nochomovitz covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Arcus Biosciences, and Sarepta Therapeutics. According to TipRanks, Nochomovitz has an average return of 5.3% and a 41.72% success rate on recommended stocks.